Aclaris Therapeutics (ACRS) Reports Q4 Loss of $0.28/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.28), versus ($1.76) reported last year.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
• Evercore upgrades Legrand on datacenter growth, cuts Siemens on margins
• CIGNA (CI) PT Raised to $387 at Bernstein SocGen